Stockreport

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis [Globe and Mail, The (Toronto, Canada)...

Eupraxia Pharmaceuticals Inc.  (EPRX) 
PDF Consistent improvement in patient-reported outcomes with six of six evaluable patients in the fourth and fifth cohorts experiencing a reduction in symptom (SDI ) scores [Read more]